A placebo-controlled, double-blind comparison of clobazam and diazepam in the treatment of anxiety.
In a randomized, placebo-controlled, double-blind study, the efficacy and safety of clobazam and diazepam were compared in 114 anxious outpatients. During the 4-week double-blind phase of the study, the mean daily dose was 59 mg for clobazam and 25 mg for diazepam. Results indicate statistically significant efficacy, measured by both patient and physician rating scales, for both active drugs compared to placebo. The incidence of sedation was similar for the two active treatment groups; dizziness was more frequent in the diazepam group.
D000328:Adult; D000553:Ambulatory Care; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000078306:Clobazam; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use*; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011897:Random Allocation
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D010919:Placebos; D001569:Benzodiazepines; D000078306:Clobazam; D003975:Diazepam